Drugs / rAAV2-VMD2-hMERTK
rAAV2-VMD2-hMERTK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01482195 | Aug 2011 → Aug 2013 | retinitis pigmentosa | King Khaled Eye Specialist Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2-VMD2-hMERTK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01482195 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus” NCT01482195 ↗ |